This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock CPSR vs. MOR, GMTX, MENS, CALT, ZYME, SBTX, MBX, AVTE, CYBN, and BIOAShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include MorphoSys (MOR), Gemini Therapeutics (GMTX), Jyong Biotech (MENS), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Aerovate Therapeutics (AVTE), Cybin (CYBN), and BioAge Labs (BIOA). Capstar Special Purpose Acquisition vs. Its Competitors MorphoSys Gemini Therapeutics Jyong Biotech Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Aerovate Therapeutics Cybin BioAge Labs Capstar Special Purpose Acquisition (NYSE:CPSR) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations. Is CPSR or MOR more profitable? Capstar Special Purpose Acquisition has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Capstar Special Purpose Acquisition's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Capstar Special Purpose AcquisitionN/A N/A N/A MorphoSys -226.79%-694.31%-22.55% Which has more volatility & risk, CPSR or MOR? Capstar Special Purpose Acquisition has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Do insiders & institutionals hold more shares of CPSR or MOR? 64.9% of Capstar Special Purpose Acquisition shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, CPSR or MOR? Capstar Special Purpose Acquisition has higher earnings, but lower revenue than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/AMorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media prefer CPSR or MOR? In the previous week, MorphoSys' average media sentiment score of 1.08 beat Capstar Special Purpose Acquisition's score of 0.00 indicating that MorphoSys is being referred to more favorably in the news media. Company Overall Sentiment Capstar Special Purpose Acquisition Neutral MorphoSys Positive SummaryCapstar Special Purpose Acquisition beats MorphoSys on 5 of the 9 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$847.49M$780.62M$5.62B$20.90BDividend YieldN/A4.84%4.64%3.65%P/E RatioN/A1.1930.1628.77Price / SalesN/A36.60463.1459.67Price / CashN/A19.5637.7222.93Price / Book-20.826.558.455.44Net Income-$15.30M-$4.39M$3.26B$994.60M Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$24.57+0.2%N/A+275.6%$847.49MN/A0.002MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsGMTXGemini TherapeuticsN/A$59.79+1.4%N/A+30.1%$2.59BN/A-59.7930MENSJyong BiotechN/A$28.93+23.3%N/AN/A$1.78BN/A0.0031News CoverageGap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks3.2401 of 5 stars$12.54-0.5%$21.00+67.5%+25.7%$873.83M$93.38M-8.36460News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSBTXSilverback TherapeuticsN/A$17.38+1.2%N/A+51.0%$626.69MN/A-7.1883High Trading VolumeMBXMBX Biosciences2.5626 of 5 stars$11.95-4.7%$37.63+214.9%N/A$399.42MN/A0.0036News CoverageGap UpAVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-87.7%$199.71MN/A-2.3020News CoverageGap UpHigh Trading VolumeCYBNCybin1.9634 of 5 stars$7.57-1.4%$85.00+1,022.9%N/A$178.58MN/A-1.7350Positive NewsBIOABioAge LabsN/A$4.44+0.5%N/AN/A$158.46MN/A0.00N/ANews CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Jyong Biotech Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors Silverback Therapeutics Competitors MBX Biosciences Competitors Aerovate Therapeutics Competitors Cybin Competitors BioAge Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access